Trial Profile
An Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of S-033188 after Administration of a Single Dose to Otherwise Healthy Pediatric Patients Aged 6 Months to < 12 Years with Influenza
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Sep 2019
Price :
$35
*
At a glance
- Drugs Baloxavir-marboxil (Primary)
- Indications Influenza A virus infections; Influenza B virus infections
- Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Shionogi
- 20 Sep 2019 Results published in the Clinical Infectious Diseases
- 18 Dec 2017 Status changed from recruiting to completed.
- 15 Nov 2016 New trial record